Phone: (707) 546-5553
Email Us
1140 Sonoma Avenue 1-A
Santa Rosa, CA 95405

Radiation-free prostate cancer treatment

Focused ultrasound therapy is here: Are you ready?

A new, highly disruptive therapeutic technology called focused ultrasound is transforming – standards of care around the globe.

In this series, we asked speakers at the Milken Institute Global Conference to answer: How does one build a meaningful life in the age of technological disruption? Join the conversation by writing your own article here and including #MIGlobal.

A new, highly disruptive therapeutic technology called focused ultrasound is slowly but definitively influencing – and on the verge of transforming – standards of care around the globe. This game-changing, noninvasive treatment option for a wide variety of serious medical disorders has the potential to be an alternative or adjunct to surgery, radiation therapy, drug delivery, and cancer immunotherapy, while decreasing cost of care and improving outcomes for millions worldwide. If it sounds too good to be true, it isn’t. Focused ultrasound has been named one of the 50 greatest inventions by TIME magazine, credited with “changing medicine” by Fortune magazine, and just this month was named a top 10 clinical research achievement of 2016 by the Washington, DC-based Clinical Research Forum.

Innovation breeds innovation, but also, modification. Once fully developed and implemented – months to decades from now depending on the clinical indication – focused ultrasound will have widespread impact on healthcare constituents including physicians, treatment facilities, and manufacturers of legacy therapy equipment, among others. This process has in fact already begun. Focused ultrasound will also bring about major change to referral patterns, treatment paradigms, practice guidelines, and equipment acquisition as the technology transitions to a mainstream therapy.

In order to benefit from these changes, stakeholders – perhaps your organization or yourself – must be prepared to enter the field early on. And for many, “early on” means now.

What is focused ultrasound?

Focused ultrasound, or FUS, uses ultrasonic energy to target tissue deep in the body without incisions or radiation. With more than 22 regulatory approvals around the world to date, including five by the US Food and Drug Administration and more than 50 additional clinical indications in various (mostly early) stages of development, FUS may treat a disparate range of diseases including: Parkinson’s; Alzheimer’s; depression; obsessive-compulsive disorder; arthritis; back pain; and, tumors of the brain, breast, prostate, liver and pancreas. It has the potential to be as revolutionary to therapy as magnetic resonance scanning (MRI) has been to diagnosis.

The basic principle is analogous to using a magnifying glass to focus beams of sunlight on a single point to burn a hole in a leaf. With focused ultrasound, multiple intersecting beams of ultrasound energy are concentrated on a target deep in the body with extreme precision and accuracy (sparing adjacent normal tissue). Where each individual beam passes through the body there is no effect. But at the focal point where the beams converge, the focused ultrasound energy induces a variety of biologic effects including: destroying tissue, stimulating the body’s immune response, and enhancing the delivery of drugs. The location of the focal point and the treatment effect is guided and controlled in real time by ultrasound or MR imaging.

Besides patients, who will focused ultrasound affect?

Three healthcare industry groups will be particularly impacted by the widespread adoption of FUS. First, consider the manufacturers of legacy therapy equipment (e.g., linear accelerators for radiation therapy and robotic surgical devices) to which focused ultrasound is an existential threat. These manufacturers would be wise to begin redistributing resources from their traditional product lines now to invest in new FUS technology. Such companies are in fact well-positioned to do so as they already have the functioning sales, marketing, support and distribution channels in place. It is clear that once the medical community broadly understands the capabilities of focused ultrasound, many legacy therapy equipment options will quickly become obsolete.

Physicians will also benefit from entering the FUS field sooner rather than later. In the current environment, many physicians – not all – can unfortunately be motivated by money, time and outcome, in that order. As focused ultrasound advances, they will need to become educated and trained in utilizing FUS technology, and adopt it as part of their practice, even in cases where the economics on a per procedure basis are less favorable than current therapy alternatives. If they choose not to, patients seeking FUS – and demand is growing – will simply find a physician who will. Of note: focused ultrasound centers worldwide are reporting a backlog of several hundred essential tremor patients desiring FUS, and a nationwide study of nearly 1,000 US uterine fibroid sufferers (published in the October 2013 issues of both the American Journal of Obstetrics and Gynecology and the Journal of Women’s Health) found that when presented with fibroid treatment descriptions, the majority surveyed (60%) rated focused ultrasound as their top treatment choice.

Finally, now is also the time for hospitals and clinics to consider becoming early adopters of focused ultrasound. Doing so will enhance their reputation as being on the leading edge of medical care, and will provide a competitive differential over institutions that have not yet acquired FUS technology (see above regarding patient demand and preference). Additionally, offering focused ultrasound will create a halo effect for the hospital or clinic when patients are referred for this cutting-edge treatment and found to not be a candidate; these patients will often choose to stay with the practice and receive an alternative treatment, increasing market share for the institution.

The future is now

We are all aware that medical device development and adoption occurs exponentially; with focused ultrasound we are right now at the beginning of the inflection point of the curve. Our goal is to treat hundreds of thousands of patients annually and we are well on our way, with 15,000 FUS treatments performed worldwide in 2014, approximately 25,000 treatments in 2015, and a more than double increase to 50,000-plus patients treated in 2016. In other words, focused ultrasound is about to evolve into a robust medical field, with the pace of research and development, publications, patient treatments and the number of device manufacturers all increasing rapidly in the past few years.

Still, there remains an enormous amount of work to be done, and many barriers to overcome, before the technology becomes a standard of care that can help millions of patients. But we are closer than ever. When the potential of focused ultrasound is realized and it becomes a mainstream therapy, it will result in changes that will benefit countless patients and impact physicians, payers/providers, manufacturers, hospitals/clinics, caretakers, etc., around the globe. It’s coming. It is reinventing care. Are you ready?

Find out more at www.fusfoundation.org

About the Author: Neal F. Kassell, M.D., is the founder and chairman of the Focused Ultrasound Foundation. He was a Professor of Neurosurgery at the University of Virginia from 1984 until 2016 and was the Co-Chairman of the department until 2006. He received both his undergraduate and medical education at the University of Pennsylvania. In April 2016, Dr. Kassell was appointed by Vice President Joe Biden to the National Cancer Institute’s Blue Ribbon Panel for Cancer Moonshot Initiative. Dr. Kassell has contributed more than 500 publications and book chapters to the literature and is a member of numerous medical societies in the United States and abroad.

The Focused Ultrasound Foundation is a medical research, education, and advocacy organization created as the catalyst to accelerate the development and adoption of FUS, shortening the time from laboratory research to widespread patient treatment. 

By | May 4th, 2017|HIFU, News, Prostate Cancer|0 Comments

Santa Rosa Urologist Dr. Michael Lazar is Making History with a Nonsurgical, Outpatient Treatment for Prostate Cancer

Dr. Lazar and his staff are proud to be early leaders in the usage of HIFU.

Dr. Lazar and his staff are proud to be early leaders in the usage of HIFU.

High-intensity focused ultrasound (HIFU) waves target cancer cells with precision in a one-to-four-hour procedure that has little or no side affects and a quick recovery rate, giving those diagnosed with prostate cancer another choice over surgery or radiation.

HIFU has been used in other countries for years, and Dr. Lazar has been instrumental in bringing this innovative treatment to the United States. It was approved by the Food and Drug Administration last October, and he has since been performing the procedure at San Francisco Surgery Center for patients who travel from across the country to receive this leading edge treatment.

“The oncological results for HIFU are broadly comparable to radical surgery or radiation but the side effects are less,” says Dr. Lazar. “If the HIFU procedure is performed in the morning, a patient is typically up and around by dinnertime and can often return to normal activity within a few days without the use of pain-killers.”

Dr. Lazar has recently become involved with HIFU Prostate Services, LLC as their Medical Director.  HIFU Prostate Services is the first company to establish centers in the United States offering Sonablate HIFU technology. HIFU Prostate Services makes the non-invasive treatment option available through partnerships with some of the largest urology practices and experienced physicians that establish Sonablate HIFU Centers of Excellence.  Urologists are able to create their own HIFU program and offer treatment within their region. These centers also offer training and proctorship opportunities.

Along with serving as the Medical Director of HIFU Prostate Services, LLC. Dr. Lazar is also a clinical partner with his HIFU Center of Excellence at the state-of-the-art SFSC in downtown San Francisco. Dr. Lazar and his staff are proud to be early leaders in the usage of HIFU. He has worked tirelessly with SonaCare, the manufacturer of the instruments, to bring this innovative service for prostate cancer treatment to patients in the United States.

The HIFU technique is also being developed to treat many other types of cancer including breast, uterine, liver, kidney, and brain.

For those with prostate cancer, HIFU treatment is most effective for patients with early stage cancer, where it is localized to the prostate. It is performed on an out-patient basis that takes one to four hours. A urinary catheter is placed after the procedure for one to three weeks.

While some patients might experience slight irritation, “some patients can have a catheter and they don’t even know it.”

The procedure preserves healthy tissue and nerves, so urine flow and erectile function is maintained in a high percent of cases, as compared to radical surgery or radiation.

Another advantage is recovery time. With surgery or radiation treatment, recuperation time for patients is six to eight weeks, whereas HIFU patients return to normal activities within days.

Dr-michael-lazarDr. Lazar has been treating U.S. prostate cancer patients in Mexico since 2007, where he performed hundreds of outpatient procedures at a U.S. Joint Commission approved bilingual hospital. There, he also served as a HIFU instructor for other physicians and is now training doctors in San Francisco.

Because the treatment is so new, it will take another couple of years before it will be routinely covered by insurance. Those with non-Medicare insurance may get reimbursed to varying degrees.

“What will really make this explode is when the insurance companies are routinely covering the procedure and it will become widely available to all patients. The costs for this procedure are drastically less than for radical surgical and radiation procedures, and with fewer complications so insurance companies will be incentivized to cover it,” Dr. Lazar commented.

As soon as more doctors are trained to perform the procedure in San Francisco, Dr. Lazar plans to bring the treatment to his Santa Rosa office.

“I expect as word gets out there will be a progressive demand for this procedure, so training physicians will be a high priority. It’s already expanding rapidly and we put in an order for our tenth machine,” said Dr. Lazar, adding he won’t be giving up his general urology practice any time soon. “This is what I love to do.”

 

 

 

HIFU: Prostate Cancer Treatment Has 97% Survival Rate

A prostate cancer treatment which is rarely offered on the NHS may give patients a 97% chance of survival after five years, a landmark study has suggested. The so-called “male lumpectomy” treatment works by treating just the prostate cancer tumor with High Intensity Focused Ultrasound (HIFU).

It is said to have “significantly fewer side effects” than traditional treatments and delivers high rates of cancer control. Prostate cancer is the most commonly diagnosed cancer in men, the second most common cause of cancer-related death in the US and the third most common cause in Europe. While already cleared by the US Food and Drug Administration (FDA), HIFU treatment is only available in very few centres in the NHS.

For more information about HIFU available in the U.S., to make an appointment call (707) 546-5553 or visit our at: www.californiahifu.com

Read the full story …

By | March 24th, 2016|HIFU, News|0 Comments

First Prostate Cancer Patient Treated with Minimally Invasive HIFU on West Coast

Dr. Michael Lazar performing first HIFU surgery on the West Coast at San Francisco Surgery Center

Dr. Michael Lazar performing first HIFU surgery on the West Coast at San Francisco Surgery Center

November 18, 2015. San Francisco, CA – HIFU Prostate Services, LLC, a leading provider of minimally- invasive prostate cancer treatment, using High Intensity Focused Ultrasound (HIFU), announced that physician partner and Medical Director, Michael J. Lazar, MD treated the first prostate cancer patient in California with minimally invasive HIFU on November 18, in San Francisco at the San Francisco Surgery Center (SFSC). This will be the second patient ever treated in the country using Sonablate HIFU technology.

HIFU Prostate Services has partnered with Lazar and SFSC to establish a HIFU Center of Excellence where patients can receive the recently FDA-cleared Sonablate HIFU treatment. SFSC is located in downtown San Francisco, near Union Square, which offers patients a state-of-the-art facility in downtown that is convenient to hotels and the airport for men who will be traveling from around the country for this non-invasive treatment.

Lazar, who also serves as Medical Director of HIFU Prostate Services, has been working with HIFU since 2007, and was one of three physicians who proctored cases during clinical trials. Lazar will offer HIFU treatment to qualified patients and also provide medical guidance and serve as a proctor to physicians that are being trained on the Sonablate® HIFU system in San Francisco and surgery centers around the country.

Kevin Wienke, Administrator of the San Francisco Surgery Center states, “The Center is proud to be able to receive one of the first Sonablate® HIFU Systems in the country and to partner with Dr. Lazar and HIFU Prostate Services to offer our patients a viable option for prostate cancer.”

John W. Linn, chief executive officer of HIFU Prostate Services said, “The Sonablate® is the first device to receive regulatory authorization from the FDA for the ablation of prostate tissue. HIFU has been available in other countries for more than 10 years, but we are proud to be the first to make this game-changing technology available in the United States”.

Since 2004, approximately 4,000 U.S. men have been treated outside the U.S. where this technology is approved in over 30 countries. HIFU offers an effective treatment for localized prostate cancer with significantly less risk of common side effects, such as impotence and incontinence, which are typically reported with surgery and radiation.

Ken Hicks, a patient of Dr. Lazar’s who received HIFU treatment in 2007 in Puerto Vallarta, Mexico says, “Finally men in the U.S. can receive this innovative, minimally invasive therapy for their prostate cancers without traveling internationally. I still can’t believe I was eating dinner on the beach just hours after my HIFU procedure and I am doing great after 7 years. I highly recommend Dr. Lazar and HIFU to anyone who is eligible for this incredible procedure.”

About Dr. Michael Lazar

Lazar HIFU

A great medical partnership begins in San Francisco. Kevin Wienke (L), Administrator SF-SC and Dr. Michael Lazar (R), Director of HIFU Prostate Services.

Dr. Lazar is currently the Medical Director of HIFU Prostate Services (HPS) and clinical partner with HPS and SFSC with the HIFU program. He has been certified by the American Board of Urology four times and has practiced in Santa Rosa, Calif. since 1983. He is chairman of the Board of Redwood Health Services, Inc. providing insurance products for employee groups. Lazar is also CEO and managing director of Santa Rosa Surgical Management Company, LLC that manages the ambulatory surgery center at Santa Rosa Memorial Hospital. Lazar received his urology training at Louisiana State University in New Orleans, La. and is a graduate of University of Arkansas Medical School.

For more information on Dr. Lazar, visit www.californiahifu.com

About HIFU Prostate Services, LLC

HIFU Prostate Services (HPS) was founded in 2015 to provide men access to a less invasive treatment option for prostate disease focused on preserving quality of life. The mission of HPS is to partner with physicians to deliver the highest quality of care, support and technology to the patient and to the urology community for the treatment of localized prostate cancer using high intensity focused ultrasound (HIFU). HPS is lead by a seasoned management team with over 50 years of experience in the healthcare industry and over 30 years focused on HIFU technologies The company is headquartered in Charlotte, NC.

For additional information, visit www.hifuprostateservices.com.

By | November 18th, 2015|Dr. Michael Lazar, HIFU, News|0 Comments

North Bay Business Journal article on Dr. Michael Lazar — HIFU: poised for approval by FDA

Click to view full story from North Bay Business Journal …. A nonsurgical, outpatient treatment for prostate cancer, with a low rate of side effects, is poised for approval by the U.S. Food and Drug Administration within the next few weeks.  Treatment with high-intensity focused ultrasound (HIFU) waves use heat focused at a specific location to destroy the area of the prostate gland affected with cancer, while any tissue outside of the focal point remains unharmed.  “The oncological results for HIFU are broadly comparable to radical surgery or radiation but the side effects are less,” said Dr. Michael Lazar, a urology specialist in Santa Rosa.  HIFU is most effective for patients with early stage prostate cancer where the cancer is localized to the prostate. The procedure preserves healthy tissue and preserving nerves, urine flow and erectile function in about 80 percent of cases compared to 40 percent–50 percent with surgery or radiation.  HIFU is also performed on an out-patient basis, taking one to four hours. A urinary catheter is inserted after the procedure and must be kept in place for one to three weeks. The most common side effects are infections in the prostate area, and incontinence, to a lesser degree than other therapies.  Click to view full story from North Bay Business Journal ….

High Intensity Focused Ultrasound (HIFU) Therapy is Gaining International Acceptance for the Treatment of Medical Conditions

your-questions-answeredA growing number of international medical organizations have already adopted High Intensity Focused Ultrasound (HIFU) therapy for treating an increasing number of conditions, and as a viable option to traditional invasive surgery, according to Dr. Michael Lazar, a Santa Rosa, California-based Urologist and a leading advocate for HIFU as an effective treatment for prostate cancer.

Dr. Lazar states, “The scientific community has known for years that high heat kills cancer. But only in recent years has the science advanced to the point where focused ultrasound energy can be used to provide pinpoint accuracy, sparing healthy tissue and preserving nerves, urine flow and erectile function in a majority of cases compared with traditional procedures, while also delivering the required amount of heat needed to destroy, or ablate, cancer.”

Today HIFU is being deployed around the world, especially in Europe, for the treatment of abdominal kidney tumors, urological cancers, uterine fibroids, and to relieve neuropathic pain associated with bone cancer, in addition to being a non-invasive treatment for prostate cancer. Medical literature also reports the use of HIFU in treating liver, breast and brain tumors as well as other conditions.”

For example, according to the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) located in Vienna, Austria, positive results were achieved with transcranial Magnetic Resonance MR-guided focused ultrasound surgery (tcMRgFUS) as a non-invasive treatment of essential tremors, neuropathic pain and Parkinson’s disease. CIRSE also reports that there have also been some investigations into the use of HIFU for temporarily opening the blood-brain barrier, allowing absorption of drugs into the brain.

Furthermore, a minimally invasive catheter-based HIFU system — designed to ablate heart tissue responsible for atrial fibrillation — has been approved for use in Europe and is undergoing an FDA approved trial in the United States.

“Adoption of HIFU has proceeded at a faster rate among international medical communities than in the United States, however, there are hopeful signs that this technique will soon be available to a broader range of patients here at home so they will not have to travel to hospitals outside of the U.S. to take advantage of this procedure,” Dr. Lazar said.

For more information about Dr. Michael Lazar, go to the HIFU website or call (707) 546-5553. His office is located at 1140 Sonoma Ave #1A, in Santa Rosa, CA 95405.

Indianapolis, Indiana-based SonaCare Medical LLC, a leading developer of minimally-invasive HIFU technology, is bringing several HIFU systems to market to meet growing global demand. SonaCare Medical, LLC, serves customers around the world through its family of affiliate companies including: USHIFU, International HIFU and Focus Surgery. For additional information, go to: www.sonacaremedical.com.

September is Prostate Cancer Awareness Month

Get a Checkup, Have a PSA Blood Test and Learn About Symptoms of the Disease as well as Treatment Options

Prostate cancer is the second leading cause of death following lung cancer, and about one man in 38 will die of the disease. However, statistics show that most men diagnosed with the prostate cancer do not die from it, and more than 2.9 million men in the U.S. who were found to have this cancer are alive today. But why take a chance? A simple screening involving an annual blood test to measure PSA levels gives doctors a way to assess the presence and pace of the disease and the need for ongoing monitoring, a biopsy or direct intervention.September is national Prostate Cancer Awareness Month. About 220,800 new cases of this type of cancer are reported each year, along with 27,540 deaths attributed to the disease annually. One in seven men will be diagnosed with prostate cancer during their lifetime. While only one man in 10,000 will typically get prostate cancer under age 40, the risk increases to six of every 10 men by age 65, according to the American Cancer Society.

Prostate cancer is the second leading cause of death following lung cancer, and about one man in 38 will die of the disease. However, statistics show that most men diagnosed with the prostate cancer do not die from it, and more than 2.9 million men in the U.S. who were found to have this cancer are alive today. But why take a chance? A simple screening involving an annual blood test to measure PSA levels gives doctors a way to assess the presence and pace of the disease and the need for ongoing monitoring, a biopsy or direct intervention.

“Why is there such a difference between cancers? Some prostate cancer is very aggressive and progresses quickly, while other forms take many years to become life threatening,” said Michael Lazar, a noted urologist with a practice in Santa Rosa, California and a leading proponent of non-invasive High Intensity Focused Ultrasound (HIFU) therapy for prostate cancer treatment.

You have a number of options if it is determined that you have this disease. These include traditional surgery to remove the prostate gland, radiation (including inserting irradiated pellets into the prostate), cryotherapy (freezing of the prostate), or non-invasive HIFU therapy using sound waves to pinpoint cancer cells and destroy them without damage to surrounding healthy tissue and minimal blood loss.

Side effects associated with invasive surgical procedures including a hospital stay, a longer recovery period plus scaring, adhesions and blood loss. There is also the risk of incontinence, erectile dysfunction (ED) and a decline of libido. Radiation can ionize otherwise healthy cells that can turn into cancer latter in life. With cryotherapy, side effects include 90% to 100% ED and urethral tissue scaring that can obstruct voiding. The HIFU procedure is virtually painless, takes only a few hours, and there are fewer side effects, thereby maintaining the quality of life. Most patients are up and around the same day.

In most instances, there are no significant symptoms during the early stages of prostate cancer, and symptoms may vary from one man to another, or can be caused by other conditions. However, there are some urinary symptoms that could signal cancer including: pain or a burning sensation while urinating as well as difficulty in starting or stopping, frequent urges to go during the night, an uncontrollable bladder, a decreased flow of the urine stream, or blood in the urine. Other symptoms include painful ejaculation or difficulty in getting an erection, swelling in the legs or pelvic area, pain or numbness in the feet, legs or hips, constant bone pain leading to fractures and blood in the semen.

“My advice to every man is to obtain a baseline PSA after age 40, then yearly exams and PSA tests after 50 years of age. For those having to make a treatment choice for prostate cancer, consider all options including HIFU. While not currently available in the U.S., HIFU is pending FDA approval and is available internationally at a full-service hospital in Puerto Vallarta, Mexico, where dozens of successful HIFU procedures have been performed by me and my highly trained team,” Dr. Lazar said.

For additional information, go to the website at www.californiahifu.com, or contact Dr. Michael Lazar’s office at (707) 546-5553. His office is located at 1140 Sonoma Ave #1A, Santa Rosa, CA 95405.

Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer

New Hardware and Software Increases Accuracy For Targeting Malignant Cells, Sparing Healthy Tissue

SonaCare Medical, LLC, the makers of innovative High Intensity Focused Ultrasound (HIFU) medical devices for the treatment of prostate cancer, has announced the roll-out of its newest technology – called Sonafuse Profuse – introduced this summer at the treatment center in Puerto Vallarta, Mexico.

The Sonablate®  technology currently in use at the San Javier Marina Hospital has been updated with powerful new hardware components and the latest generation “3G” software including image fusion. Puerto Vallarta is now one of only three international treatment sites in the Americas offering image fusion and the newest software offering the benefits of multi-mode imaging that sees the outside and inside of the targeted area at the same time.

“Until now, Magnetic Resonance Images (MRI) had to be viewed separately from live HIFU images by doctors performing the procedure,” according to Dr. Michael Lazar, a leading urologist and pioneer of HIFU who has been treating prostate cancer patients in Puerto Vallarta since 2007. “Now using advanced software, both image sets are combined enabling us to gain an even clearer picture of cancer cells and their precise location so they can be more accurately, and individually, targeted using ultrasound energy.”

Sonafuse Profuse technology fuses a previously obtained magnetic resonance image (MRI) with live ultrasound during the HIFU procedure. This allows the visualization of regions of abnormality visible with MRI, but not normally visible with ultrasound during the procedure for targeted treatment. The fusion program is based on Artemis Profuse software from Eigen, one of three SonaCare Medical fusion partners that provide seamless integration with physicians’ targeted biopsy systems.

Dr. Lazar said there are many benefits associated with advanced HIFU therapy, including sound-based, tissue sparing, non-surgical intervention for the treatment of prostate cancer and more favorable outcomes for patients.

He said modern imaging technology is changing today’s urological cancer landscape, enabling doctors to increase their detection of genitourinary cancer as well as better tumor and cancer cell visualization, especially among smaller confined tumors. He said it is also helping physicians achieve better, targeted biopsies and helps in the diagnosis of prostate cancer among younger patients.

HIFU is also being used in conjunction with CT scans to detect small, incidentally discovered, kidney renal masses – as well as for mpMRI prostate scans to identify specific regions of interest for targeted biopsy and ablation therapy.

For more information contact Dr. Michael Lazar, visit the California HIFU website, or call (707) 546-5553. Dr. Lazar’s office is located at 1140 Sonoma Ave #1A, Santa Rosa, CA 95405.

Active Ft. Bragg resident believes that “HIFU’s time has come”

Lazar HIFU testimonial 8.18

During annual checkups, Dennis Tavares’ primary doctor noticed two successive PSA increases and referred him to Urologist Dr. Michael Lazar. A sonic scan showed a series of dark spots. His prostate was getting bigger and was losing its shape and smoothness. Dr. Lazar performed a biopsy. Cancer cells were small, so there was little threat that they had spread. “My choices included getting a full or a partial prostate treatment. I chose to have only a partial oblation, with Dr. Lazar's concurrence, since the area with cancer was limited to only a section of the prostate. I got an MRI in Santa Rosa, had passports and was ready to go. We flew to Puerto Vallarta. The HIFU procedure was performed in a first-class medical center – very clean, neat and well furnished and everyone spoke English and very supportive. Dr. Lazar explained that I would be given spinal anesthesia so I would not move during the less than three-hour procedure. The next thing I knew I was waking up and just as Dr. Lazar predicted, with HIFU there was no bleeding and little to no chance of infection.”

 

By | August 18th, 2015|Dr. Michael Lazar, HIFU, Testimonials|0 Comments

International HIFU Physician Dr. Michael Lazar

It has been very exciting to be able to offer HIFU to men with prostate cancer the past 6 years. The utility of the procedure continues to grow, with the evolution from merely whole gland therapy to the possibility of focal therapy. With MRI imaging improvements, we can not only limit treatment to the cancer focus in appropriate men, we can now better determine which patients are likely to have successful outcomes with whole gland therapy. Tissue Change Monitoring (TCM) has inspired me to modify the treatment on whole glands to lessen the risk of complications.

It is impressive that many of my patients have done the math and found HIFU to be a relative bargain due their ability to go right back to work. When one considers the convalescent period after radical prostatectomy, or the weeks involved with radiation therapy, not mention the higher side effect profile with both, the cost of HIFU becomes less an obstacle to choosing this innovative option. I am very enthusiastic about teaching this procedure to my colleagues going forward.

To learn more about or be connected to Dr. Lazar please call 1-866-553-1629 or email nurse@internationalhifu.com.